TY - JOUR
T1 - Transdermal fluorescence detection of a dual fluorophore system for noninvasive point-of-care gastrointestinal permeability measurement
AU - Dorshow, Richard B.
AU - Johnson, J. R.
AU - Debreczeny, Martin P.
AU - Riley, I. Rochelle
AU - Shieh, Jeng Jong
AU - Rogers, Thomas E.
AU - Hall-Moore, Carla
AU - Shaikh, Nurmohammad
AU - Rouggly-Nickless, L. Colleen
AU - Tarr, Phillip I.
N1 - Funding Information:
Bill & Melinda Gates Foundation (OPP1152812). The authors thank Lisa Balbes, Ph.D., of Balbes Consultants, LLC, for providing editorial support.
Publisher Copyright:
© 2019 OSA - The Optical Society. All rights reserved.
PY - 2019/10/1
Y1 - 2019/10/1
N2 - The intestinal mucosal barrier prevents macromolecules and pathogens from entering the circulatory stream. Tight junctions in this barrier are compromised in inflammatory bowel diseases, environmental enteropathy, and enteric dysfunction. Dual sugar absorption tests are a standard method for measuring gastrointestinal integrity, however, these are not clinically amenable. Herein, we report on a dual fluorophore system and fluorescence detection instrumentation for which gastrointestinal permeability is determined in a rat small bowel disease model from the longitudinal measured transdermal fluorescence of each fluorophore. This fluorophore technology enables a specimen-free, noninvasive, point-of-care gastrointestinal permeability measurement which should be translatable to human clinical studies.
AB - The intestinal mucosal barrier prevents macromolecules and pathogens from entering the circulatory stream. Tight junctions in this barrier are compromised in inflammatory bowel diseases, environmental enteropathy, and enteric dysfunction. Dual sugar absorption tests are a standard method for measuring gastrointestinal integrity, however, these are not clinically amenable. Herein, we report on a dual fluorophore system and fluorescence detection instrumentation for which gastrointestinal permeability is determined in a rat small bowel disease model from the longitudinal measured transdermal fluorescence of each fluorophore. This fluorophore technology enables a specimen-free, noninvasive, point-of-care gastrointestinal permeability measurement which should be translatable to human clinical studies.
UR - http://www.scopus.com/inward/record.url?scp=85078854057&partnerID=8YFLogxK
U2 - 10.1364/BOE.10.005103
DO - 10.1364/BOE.10.005103
M3 - Article
C2 - 31646033
AN - SCOPUS:85078854057
SN - 2156-7085
VL - 10
SP - 5103
EP - 5116
JO - Biomedical Optics Express
JF - Biomedical Optics Express
IS - 10
ER -